Patent Assignment
Reel/Frame 046591/0544
First Lien Patent Security Agreement
Recorded: 2018-07-19
Received: 2018-07-19
Pages: 8
Assignor
TERSERA THERAPEUTICS LLC
Executed: 2018-07-12
Assignee
MIDCAP FINANCIAL TRUST, AS AGENT
7255 WOODMONT AVENUE, SUITE 200, BETHESDA, MD, 20814, UNITED STATES
Covered Properties
(22)
Work Unit Power Supply Device
Application:
15/580,697 →
Process and Intermediates for the Synthesis of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Compounds
Application:
15/043,129 →
Process and Intermediates for the Synthesis of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Compounds
Application:
15/012,422 →
Hydrochloride Salts of 8-[1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxymethyl]-8-Phenyl-1,7-Diazaspiro[4,5]Decan-2-One and Preparation Process Therefor
Application:
14/683,871 →
Tablet Formulations Containing 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Salts and Tablets Made Therefrom
Application:
14/540,635 →
NK1 Antagonists
Application:
14/341,097 →
Process and Intermediates for the Synthesis of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one Compounds
Application:
14/043,210 →
Process and Intermediates for the Synthesis of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Compounds
Application:
14/039,367 →
Pharmaceutical Formulations: Salts of 8-[1-3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxymethyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One and Treatment Methods Using the Same
Application:
13/847,242 →
NK1 Antagonists
Application:
13/625,799 →
Pharmaceutical Formulations:Salts of 8-[1-3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxymethyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One and Treatment Methods Using the Same
Application:
13/184,926 →
NK1 Antagonists
Application:
12/967,132 →
Intravenous Formulations of Neurokinin-1 Antagonists
Application:
12/855,889 →
Tablet Formulations Containing 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Salts and Tablets Made Therefrom
Application:
12/531,966 →
Process and Intermediates for the Synthesis of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One Compounds
Application:
12/531,859 →
Hydrochloride Salts of 8-[{1-(3,5-Bis-Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One and Preparation Process Therefor
Application:
12/614,108 →
Pharmaceutical Formulations: Salts of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One and Treatment Methods Using the Same
Application:
12/487,263 →
Hydrochloride Salts of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy)-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One and Preparation Process Therefor
Application:
11/732,548 →
Pharmaceutical Formulations: Salts of 8-[{1-(3,5-Bis-(Trifluoromethyl)Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One and Treatment Methods Using the Same
Application:
11/732,663 →
NK1 Antagonists
Application:
11/358,827 →
Method for Connecting Component Delivery Tapes, Structure of the Connection, and Scissors for Component Delivery Tape, Used for the Connection Method
Application:
10/544,709 →
Nk 1 Antagonists
Application:
10/321,687 →